Trial Profile

A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Docetaxel; Gemcitabine
Indications Synovial sarcoma
Focus Therapeutic Use
Acronyms CAMPFIRE
Sponsors Eli Lilly and Company

Most Recent Events

07 Apr 2023 Status changed from suspended to discontinued.
02 Apr 2023 The trial has been completed in Germany, according to European Clinical Trials Database
30 Mar 2023 The trial has been completed in Belgium and France, according to European Clinical Trials Database

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com